Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Chief Medical Officer | May 18, 2026 | May 20, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | May 28, 2025 | May 29, 2025 |
| SERA PROGNOSTICS, INC.SERA · Entity 304 | Director | July 10, 2026 | July 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,817 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 38,817 · Balance 38,817 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
Karyopharm Therapeutics Inc.
Report date May 28, 2025 · Filed May 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.48 · Expires 2035-05-27 | Direct | 4,600 |
Reported balance
After 2025-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 4,600 · Balance 4,600 F1: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2: This option vests as to 100% of the underlying shares on May 28, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
F2: This option vests as to 100% of the underlying shares on May 28, 2026.
SERA PROGNOSTICS, INC.
Report date July 10, 2026 · Filed July 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 81,937 |
Ending reported balance
After 2026-07-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-10 · Grant · Acquired 22,426 · Balance 80,166 F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Row 2 · 2026-07-10 · Grant · Acquired 1,771 · Balance 81,937 F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10 | Direct | 34,494 |
Reported balance
After 2026-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-10 · Grant · Acquired 34,494 · Balance 34,494 F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10 | Direct | 2,725 |
Reported balance
After 2026-07-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-10 · Grant · Acquired 2,725 · Balance 2,725 F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2020 Filed Jan 13, 2020 22:02 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 2,056 | $0.00 Strike: $8.06 | $0.00 |
DisclosureSEC source: 0001209191-20-003200 · doc4.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,056 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 100% of the underlying shares on June 16, 2017. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 22:02 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,056 | $20.00 | $41,120.00 |
DisclosureSEC source: 0001209191-20-003200 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 22:02 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 2,056 | $8.06 | $16,571.36 |
DisclosureSEC source: 0001209191-20-003200 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 14:15 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 2,944 | $0.00 Strike: $8.06 | $0.00 |
DisclosureSEC source: 0001209191-19-062198 · doc4.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,056 Underlying: Common Stock · 2,944 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 100% of the underlying shares on June 16, 2017. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 14:15 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,944 | $20.00 | $58,880.00 |
DisclosureSEC source: 0001209191-19-062198 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 14:15 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 2,944 | $8.06 | $23,728.64 |
DisclosureSEC source: 0001209191-19-062198 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 12,121 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001209191-19-061520 · doc4.xml · derivative · entry 4 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Mirza Consulting Disclosed balance after: 0 Underlying: Common Stock · 12,121 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 6, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,121 | $17.18 | $122,345.19 |
DisclosureSEC source: 0001209191-19-061520 · doc4.xml · nonDerivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Mirza Consulting Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.07 to $17.415, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,000 | $17.18 | $85,890.50 |
DisclosureSEC source: 0001209191-19-061520 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Mirza Consulting Disclosed balance after: 7,121 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.06 to $17.393, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 12,121 | $1.49 | $17,999.69 |
DisclosureSEC source: 0001209191-19-061520 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Mirza Consulting Disclosed balance after: 12,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 22:26 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,342 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001209191-19-060076 · doc4.xml · derivative · entry 4 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,342 shares Expires 2023-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 1, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 22:26 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,342 | $17.02 | $90,926.18 |
DisclosureSEC source: 0001209191-19-060076 · doc4.xml · nonDerivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.75 to $17.58, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 22:26 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,000 | $17.02 | $85,108.00 |
DisclosureSEC source: 0001209191-19-060076 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,342 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.75 to $17.58, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 22:26 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,342 | $5.64 | $58,359.91 |
DisclosureSEC source: 0001209191-19-060076 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 12:58 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001209191-19-035377 · doc4.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 6, 2020, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 264 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001209191-18-049177 · doc4.xml · derivative · entry 5 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,342 Underlying: Common Stock · 264 shares Expires 2023-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 1, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 2,236 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001209191-18-049177 · doc4.xml · derivative · entry 4 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,236 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 6, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,500 | $21.00 | $52,500.00 |
DisclosureSEC source: 0001209191-18-049177 · doc4.xml · nonDerivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 264 | $5.64 | $1,489.75 |
DisclosureSEC source: 0001209191-18-049177 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 2,236 | $1.49 | $3,320.46 |
DisclosureSEC source: 0001209191-18-049177 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 29, 2018 Filed Aug 30, 2018 20:38 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001209191-18-048954 · doc4.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,236 Underlying: Common Stock · 2,500 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 6, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| August 29, 2018 Filed Aug 30, 2018 20:38 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,500 | $20.00 | $50,000.00 |
DisclosureSEC source: 0001209191-18-048954 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 29, 2018 Filed Aug 30, 2018 20:38 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 2,500 | $1.49 | $3,712.50 |
DisclosureSEC source: 0001209191-18-048954 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001209191-18-038753 · doc4.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2028-06-18 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 19, 2019, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 1,325 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001209191-18-029523 · doc4.xml · derivative · entry 5 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,736 Underlying: Common Stock · 1,325 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 6, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 675 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-029523 · doc4.xml · derivative · entry 4 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 675 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on June 18, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,000 | $18.00 | $36,000.00 |
DisclosureSEC source: 0001209191-18-029523 · doc4.xml · nonDerivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 1,325 | $1.49 | $1,967.63 |
DisclosureSEC source: 0001209191-18-029523 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 675 | $0.26 | $178.20 |
DisclosureSEC source: 0001209191-18-029523 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 21:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-019625 · doc4.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675 Underlying: Common Stock · 2,500 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on June 18, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 21:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,500 | $17.01 | $42,525.00 |
DisclosureSEC source: 0001209191-18-019625 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 21:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 2,500 | $0.26 | $660.00 |
DisclosureSEC source: 0001209191-18-019625 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:56 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-017335 · doc4.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,175 Underlying: Common Stock · 2,500 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on June 18, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:56 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001209191-18-017335 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:56 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 2,500 | $0.26 | $660.00 |
DisclosureSEC source: 0001209191-18-017335 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 21:32 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-009218 · doc4.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,675 Underlying: Common Stock · 1,500 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on June 18, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 21:32 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,500 | $14.00 | $21,000.00 |
DisclosureSEC source: 0001209191-18-009218 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 21:32 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 1,500 | $0.26 | $396.00 |
DisclosureSEC source: 0001209191-18-009218 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 401 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-008425 · doc4.xml · derivative · entry 5 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,175 Underlying: Common Stock · 401 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on June 18, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 1,099 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-008425 · doc4.xml · derivative · entry 4 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,099 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,500 | $13.00 | $19,500.00 |
DisclosureSEC source: 0001209191-18-008425 · doc4.xml · nonDerivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 401 | $0.26 | $105.86 |
DisclosureSEC source: 0001209191-18-008425 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 1,099 | $0.26 | $290.14 |
DisclosureSEC source: 0001209191-18-008425 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-17-055754 · doc4.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099 Underlying: Common Stock · 2,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,000 | $12.00 | $24,000.00 |
DisclosureSEC source: 0001209191-17-055754 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 2,000 | $0.26 | $528.00 |
DisclosureSEC source: 0001209191-17-055754 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 20:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 2,882 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-17-053151 · doc4.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,099 Underlying: Common Stock · 2,882 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 20:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,882 | $11.00 | $31,702.00 |
DisclosureSEC source: 0001209191-17-053151 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 20:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 2,882 | $0.26 | $760.85 |
DisclosureSEC source: 0001209191-17-053151 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 20:13 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 118 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-17-052587 · doc4.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,981 Underlying: Common Stock · 118 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.